Deletion of the Tumor Suppressor Gene PTEN in ETS-Fusion Positive Prostate Cancer Identifies Patients with High Risk Pathology That May Benefit from Adjuvant Radiation
Publication
, Conference
Fecteau, RE; Liu, D; Barbieri, CE; Nagar, H
Published in: International Journal of Radiation Oncology*Biology*Physics
November 2020
Duke Scholars
Published In
International Journal of Radiation Oncology*Biology*Physics
DOI
ISSN
0360-3016
Publication Date
November 2020
Volume
108
Issue
3
Start / End Page
S4 / S4
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 5105 Medical and biological physics
- 3407 Theoretical and computational chemistry
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
- 0299 Other Physical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Fecteau, R. E., Liu, D., Barbieri, C. E., & Nagar, H. (2020). Deletion of the Tumor Suppressor Gene PTEN in ETS-Fusion Positive Prostate Cancer Identifies Patients with High Risk Pathology That May Benefit from Adjuvant Radiation. In International Journal of Radiation Oncology*Biology*Physics (Vol. 108, pp. S4–S4). Elsevier BV. https://doi.org/10.1016/j.ijrobp.2020.07.2073
Fecteau, R. E., D. Liu, C. E. Barbieri, and H. Nagar. “Deletion of the Tumor Suppressor Gene PTEN in ETS-Fusion Positive Prostate Cancer Identifies Patients with High Risk Pathology That May Benefit from Adjuvant Radiation.” In International Journal of Radiation Oncology*Biology*Physics, 108:S4–S4. Elsevier BV, 2020. https://doi.org/10.1016/j.ijrobp.2020.07.2073.
Fecteau RE, Liu D, Barbieri CE, Nagar H. Deletion of the Tumor Suppressor Gene PTEN in ETS-Fusion Positive Prostate Cancer Identifies Patients with High Risk Pathology That May Benefit from Adjuvant Radiation. In: International Journal of Radiation Oncology*Biology*Physics. Elsevier BV; 2020. p. S4–S4.
Fecteau, R. E., et al. “Deletion of the Tumor Suppressor Gene PTEN in ETS-Fusion Positive Prostate Cancer Identifies Patients with High Risk Pathology That May Benefit from Adjuvant Radiation.” International Journal of Radiation Oncology*Biology*Physics, vol. 108, no. 3, Elsevier BV, 2020, pp. S4–S4. Crossref, doi:10.1016/j.ijrobp.2020.07.2073.
Fecteau RE, Liu D, Barbieri CE, Nagar H. Deletion of the Tumor Suppressor Gene PTEN in ETS-Fusion Positive Prostate Cancer Identifies Patients with High Risk Pathology That May Benefit from Adjuvant Radiation. International Journal of Radiation Oncology*Biology*Physics. Elsevier BV; 2020. p. S4–S4.
Published In
International Journal of Radiation Oncology*Biology*Physics
DOI
ISSN
0360-3016
Publication Date
November 2020
Volume
108
Issue
3
Start / End Page
S4 / S4
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 5105 Medical and biological physics
- 3407 Theoretical and computational chemistry
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
- 0299 Other Physical Sciences